By M. Marin
OTCQB: AINMF
READ THE FULL AINMF RESEARCH REPORT
AINMF believes platform is well-positioned, as use of AI in clinical development is expected to rise
NetraMark (OTCQB: AINMF), an AI company developing AI and Machine Learning (ML) solutions to help optimize pharmaceutical clinical research trial activities, AINMF believes its NetraAI platform is well-positioned to support the next-gen of clinical development as the use of AI in clinical development activities is expected to rise. As sponsors of new drugs encounter rising pressure to improve trial designs, identify responder populations and improve their insights from complex clinical datasets, according to AINMF, it supports increasing use of its AI technology.
The company believes the NetraAI platform is well-positioned to support the next generation of clinical development as the use of AI in clinical development activities is expected to rise. As it advances its business strategy and continues to position the NetraAI platform – beginning initially with oncology and central nervous system (CNS) indications – the company notes that sponsors of new drugs encounter rising pressure to improve trial designs, identify responder populations, and improve their insights from complex clinical datasets, which AINMF believes supports increasing use of its AI technology. Over time, NetraMark expects to expand its focus to a range of other medical indications.
Moving Worldwide Clinical Trials collaboration forward
Moreover, AINMF is encouraged by the continued growth of its commercial pipeline. One example is that work advances to integrate NetraAI into affiliate Worldwide Clinical Trials’ offerings. In April 2025, NetraMark formed a global agreement with leading CRO Worldwide Clinical Trials, which expects to make NetraMark's NetraAI a dedicated solution within its offerings. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries. Worldwide has about 30 years of clinical experience. Its focus on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease aligns with NetraMark’s focus on CNS and the oncology space. The two companies believe that leveraging NetraMark's NetraAI platform to identify key patient subpopulations can help Worldwide deliver insights to improve its clients’ clinical activities and enhance trial efficiency. Initially, NetraMark's AI technology will be used for Phase 2 neuroscience and oncology clinical trials and for some Phase 3 clinical studies selectively. In the future, the partners expect to use the NetraMark technology across all therapeutic areas and trial phases.
Oncology & central nervous system (CNS) initial focus; Over time, expansion to a range of medical indications expected
In the oncology space, NetraMark announced a strategic research collaboration with Fondazione per la Medicina Personalizzata (FMP) in FY 2Q26 to analyze FMP’s ROME Phase II oncology trial dataset (NCT04591431) using NetraMark’s proprietary NetraAI platform, with the objective of identifying clinically actionable insights that may inform future precision-oncology strategies and clinical trial design.
The collaboration is expected to support the company’s aim to demonstrate the value of its technology in complex, high-impact clinical research settings. In addition to leveraging NetraAI’s capabilities to uncover clinically actionable insights for FMP’s ROME program, the collaboration is also expected to enable NetraMark to advance and refine its platform and strengthen its ability to support future clinical trial design, biomarker development, and strategies for a potentially growing client base.
In addition, at the 2026 AD/PD (Alzheimer's and Parkinson's Diseases) conference in March 2026, NetraMark also introduced AI-discovered treatment-responsive subgroups from the A4 Alzheimer’s Trial. The company views this as further proof-of-concept supporting the potential of NetraAI to identify meaningful patient subpopulations in neurodegenerative disease. The company believes patient heterogeneity among people who suffer from these conditions has created challenges for clinical trial design and interpretation in the past that its platform can potentially address.
Consistent with advancing its opportunities in the CNS space, AINMF signed a new contract with a leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders to analyze data from the client’s Phase 2 clinical trial for depression. The aim is to leverage NetraMark’s platform to analyze the Phase 2 dataset to identify patient subpopulations most likely to benefit from treatment and provide insights that may inform the client’s future study design. The Company believes this engagement further supports NetraMark’s commercial focus on applying NetraAI to neuroscience and psychiatry datasets, where complex patient variability can make traditional clinical trial analyses difficult.
Growing commercial pipeline, revenue backlog
Reflecting rising interest from pharma, biotech, and clinical research players that want to leverage advanced AI-driven approaches to clinical trial design, stratification, enrichment, and interpretation, NetraMark is encouraged by its growing commercial pipeline and revenue backlog. Year-to-date in FY 2026, NetraMark has signed customer agreements representing aggregate contract value of roughly C$3.09 million, of which about C$129k has been recognized as revenue in FY 2026. AINMF believes this illustrates its ongoing commercial progress with its platform. The company has indicated that it has an additional seven proposals being reviewed. Agreements noted above follow multiple earlier partnerships NetraMark formed to grow its pipeline and/or advance R&D.
In addition, NetraMark appointed Dr. Panteli Theocharous as Fractional Chief Medical Officer to strengthen its clinical leadership team and support the global adoption of its NetraAI technology. Dr. Theocharous has extensive experience in clinical development, medical strategy, and biopharmaceutical partnerships, according to AINMF. The company believes this addition to its team will help it advance commercial and clinical engagement with drug sponsors and partners.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.